Frontiers in neurology · 2026
A unified spectrum model for the anti-GQ1b antibody syndromes: from pathophysiology to a new diagnostic framework.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
El Abdi Khalil, Bibi Fazeela, Ibrahim Muhammad, Ahmed Kanza, Nagdev Suraksha, Bibi Zulekhan, Aslam Bilal, Hassan Vohra Maham, Khan Muhammad Sarim Azad, Shah Asghar, Sammi Muhammad Saad, Khan Abdullah, Imran Hania, Sadat Said Hamid
Аннотация
BACKGROUND: Bickerstaff Brainstem Encephalitis (BBE) is a rare, post-infectious autoimmune disorder characterized by ophthalmoplegia, ataxia, and altered consciousness. Its significant clinical and serological overlap with Miller Fisher syndrome (MFS) and Guillain-Barré syndrome (GBS) creates diagnostic challenges, particularly in atypical or seronegative presentations. These conditions are collectively understood as components of the anti-GQ1b antibody syndrome, a spectrum of neuro-immune disorders.
AIMS: This review provides a clinically focused, integrative synthesis of the anti-GQ1b antibody spectrum, with an emphasis on BBE. We aim to clarify the underlying pathophysiology, delineate the range of clinical phenotypes, provide a structured framework for diagnosis that acknowledges the limitations of ancillary testing, and summarize current evidence for therapeutic strategies.
SYNTHESIS OF EVIDENCE: Pathogenesis is primarily driven by anti-GQ1b IgG antibodies, generated following infection via molecular mimicry, which trigger complement-mediated damage to ganglioside-rich neural structures. The clinical presentation ranges from purely peripheral deficits (MFS) to severe central nervous system dysfunction (BBE), with frequent BBE-GBS overlap syndromes. Diagnosis hinges on clinical recognition, supported by serology, with neuroimaging serving a crucial role in excluding mimics. Approximately one-third of clinically defined BBE cases are seronegative, suggesting alternative mechanisms. Prompt immunotherapy with intravenous immunoglobulin (IVIg) or plasma exchange is the cornerstone of management, extrapolated from GBS trials, while evidence for corticosteroids remains limited.
CONCLUSION: A structured, spectrum-based perspective remains essential for clinicians navigating the diagnostic complexities of the anti-GQ1b antibody syndromes. This updated synthesis is intended to enhance diagnostic accuracy, guide therapeutic reasoning across the full range of phenotypes, and highlight key unresolved questions to inform a future research agenda.
AIMS: This review provides a clinically focused, integrative synthesis of the anti-GQ1b antibody spectrum, with an emphasis on BBE. We aim to clarify the underlying pathophysiology, delineate the range of clinical phenotypes, provide a structured framework for diagnosis that acknowledges the limitations of ancillary testing, and summarize current evidence for therapeutic strategies.
SYNTHESIS OF EVIDENCE: Pathogenesis is primarily driven by anti-GQ1b IgG antibodies, generated following infection via molecular mimicry, which trigger complement-mediated damage to ganglioside-rich neural structures. The clinical presentation ranges from purely peripheral deficits (MFS) to severe central nervous system dysfunction (BBE), with frequent BBE-GBS overlap syndromes. Diagnosis hinges on clinical recognition, supported by serology, with neuroimaging serving a crucial role in excluding mimics. Approximately one-third of clinically defined BBE cases are seronegative, suggesting alternative mechanisms. Prompt immunotherapy with intravenous immunoglobulin (IVIg) or plasma exchange is the cornerstone of management, extrapolated from GBS trials, while evidence for corticosteroids remains limited.
CONCLUSION: A structured, spectrum-based perspective remains essential for clinicians navigating the diagnostic complexities of the anti-GQ1b antibody syndromes. This updated synthesis is intended to enhance diagnostic accuracy, guide therapeutic reasoning across the full range of phenotypes, and highlight key unresolved questions to inform a future research agenda.